A Lancet Trial Just Showed GLP-1s Can Reduce Heavy Drinking

The Addiction Connection That Surprised Researchers

In May 2026, The Lancet published a Phase 2 randomized clinical trial that generated headlines across the medical world. Researchers at Copenhagen University Hospital, in collaboration with scientists from the U.S. National Institutes of Health, tested once-weekly semaglutide in 48 adults with alcohol use disorder and comorbid obesity. Over nine weeks, patients on semaglutide showed significant reductions in both alcohol consumption and cravings compared with placebo.

This was not an isolated signal. A 2026 observational study published in the British Medical Journal analyzed data from over 600,000 U.S. veterans with type 2 diabetes and found that patients on GLP-1 receptor agonists were 14% less likely to develop a substance use disorder — encompassing alcohol, cannabis, cocaine, nicotine, and opioids — compared with patients on other diabetes medications.

Among veterans who already had pre-existing substance use disorders, GLP-1 use was associated with lower rates of emergency room visits, hospitalizations, mortality, overdose, and even suicidal thoughts or attempts.

How GLP-1s May Affect the Brain's Reward System

The biological mechanism is increasingly well-understood. GLP-1 receptors are present not only in the gut and pancreas but also in key brain regions involved in reward and addiction, including the nucleus accumbens and ventral tegmental area. These are the same circuits that drive compulsive eating, drinking, and drug-seeking behavior.

Preclinical research from the Scripps Research Institute demonstrated that semaglutide reduces binge-like alcohol consumption in both mice and rats, and modulates GABA neurotransmission in the central amygdala — a brain region critical for the transition from casual use to compulsive use.

NIH Director of the National Institute on Drug Abuse Dr. Nora Volkow summarized the clinical significance: the potential for GLP-1s to treat addiction is beginning to turn into reality.

What This Means If You Struggle with Both Weight and Alcohol

If you are considering or currently taking a GLP-1 for weight management and also have concerns about alcohol use, this research suggests you may experience a dual benefit. Many patients have anecdotally reported reduced interest in alcohol after starting semaglutide or tirzepatide — and the clinical data is beginning to explain why.

Here is what to discuss with your prescriber:

• Be honest about your alcohol use. Physicians cannot optimize your treatment plan without a complete picture. GLP-1 therapy is not a substitute for addiction treatment, but it may be a useful adjunct.
• Ask about gastric emptying. GLP-1 medications slow gastric emptying, which can change how alcohol is absorbed. Some patients report feeling the effects of alcohol more quickly or intensely. This is a safety consideration, not just a curiosity.
• Understand the limitations. This is early-stage evidence. If you have a serious alcohol use disorder, GLP-1 therapy should complement — not replace — evidence-based addiction treatment including behavioral therapy and FDA-approved medications like naltrexone.
• Monitor your patterns. If you notice a significant, spontaneous reduction in alcohol cravings after starting a GLP-1, report it to your doctor. These real-world observations contribute to the growing evidence base.